Myeloma

  1. A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients
    Primary researcher: Raija Silvennoinen

  2. A phase 1 multicenter, open-label study to assess the safety, pharmacokinetics and preliminary efficacy of cc-92480 in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
    Primary researcher: Pekka Anttila
 

 Contact information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680